Compare Amphastar Pharmaceuticals Inc (AMPH) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Live Nation Entertainment, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Live Nation Entertainment, Inc. trades at $183.14 (market cap $43.01B). The key difference: Live Nation Entertainment, Inc. is far larger — about 49.8× Amphastar Pharmaceuticals Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | LYV | |
|---|---|---|
Market Cap | $863.95M | $43.01B |
Sector | Health | Industrials |
52-Week High | $30.81 | $186.59 |
52-Week Low | $16.87 | $125.61 |
Enterprise Value | $1.26B | $45.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Live Nation (LYV) trades at $180.66, down 0.61% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $209.54. The company reported Q2 2026 EPS of $1.05, beating estimates, and revenue growth driven by strong concert demand. However, valuation metrics like a P/E of 117.49 and a P/B of 511.19 appear elevated, while net income margin remains thin at 0.51% for 2025.
The outlook is supported by robust fan attendance and raised full-year expectations, but risks include high debt levels, legal uncertainties, and cost pressures. With 87% of analysts rating it a buy, the stock offers growth potential contingent on execution amid competitive and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
